deCODE genetics (DCGN) and Celera Corporation (CRA) announced the signing of agreements under which deCODE has granted Celera non-exclusive worldwide licenses to deCODE's genetic markers for increased risk of major cardiovascular and metabolic diseases, including heart attack, stroke, atrial fibrillation (AF) and type 2 diabetes (T2D). These markers can be incorporated into laboratory tests for assessing and managing individual risk of these diseases.
Under the terms of the agreements, deCODE will receive an upfront payment and royalties on sales of testing products incorporating its markers. Additional financial details were not disclosed.
No comments:
Post a Comment